Missing/wrong data?
Log in to edit
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
scientific article
Author/s
author: Ahmed Mohamed Abdel Ghany Othman, Ahmed A Othman, Heikki Mansikka, Alan Kivitz, Robert William Padley
Work details
Publication date
November 8, 2017
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.